Kyntra Bio Inc
KYNB Healthcare Biotechnology
In the quarter to June 2026, revenue fell 209.4%, EPS grew 257.5% and free cash flow fell 131.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow KYNB
Kyntra Bio Inc (KYNB) Beneish M-score
Kyntra Bio Inc's Beneish M-score for fiscal 2025 is −4.57; values above −1.78 are the model's flag for possible earnings manipulation — a statistical screen, not a finding.
Beneish M-score, annual
Embed this chart
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|---|---|
| FY2025 | −4.57 | (1.02) |
| FY2024 | −3.55 | (0.16) |
| FY2023 | −3.39 | 0.48 |
| FY2022 | −3.87 | (2.21) |
| FY2021 | −1.66 | 2.00 |
| FY2020 | −3.66 | (0.99) |
| FY2019 | −2.67 | (4.96) |
| FY2018 | 2.29 | 5.48 |
| FY2017 | −3.19 | 0.41 |
| FY2016 | −3.60 | (0.55) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | 2.07 | — | 1.90 | |
| Gross margin index | 0.52 | — | 0.27 | |
| Asset quality index Asset quality not computable — index set to 1 | 1.00 | — | Set to 1 | 0.40 |
| Sales growth index | 0.22 | — | 0.19 | |
| Depreciation index Depreciation not reported — index set to 1 | 1.00 | — | Set to 1 | 0.12 |
| SG&A index | 2.58 | — | −0.44 | |
| Total accruals to total assets | (0.45) | — | −2.09 | |
| Leverage index | 0.25 | — | −0.08 | |
| Beneish M-score | Low — no pattern the model associates with manipulation | −4.57 | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| KYNB Kyntra Bio Inc | −4.6× |
| IMMP Prima BioMed Ltd compare | −3.5× |
| EVAX Evaxion A/S - Sponsored ADR compare | −2.2× |
| COCP Cocrystal Pharma, Inc. compare | −1.7× |
| CYAD Celyad SA compare | 10.5× |
| ESLA Estrella Immunopharma, Inc. compare | — |
| PLRZ Polyrizon Ltd. compare | — |
| CNTX Context Therapeutics Inc. compare | — |
| QNTM Quantum Biopharma Ltd. compare | — |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI